Daré Bioscience, Inc. (DARE) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates a mixed outlook. The 25% revenue growth is positive, but the net loss and increased R&D expenses raise concerns. The dual path strategy offers potential but carries regulatory and execution risks. No new partnerships or changes in guidance were mentioned, and shareholder return plans were not discussed. Without information on market cap, a neutral sentiment is appropriate, reflecting balanced positive and negative factors.
Key Financial Performance
Revenue The company reported revenue of $2.5 million for Q1 2026, representing a 25% increase year-over-year. This growth was attributed to higher sales of proprietary formulations and expanded market reach.
Net Loss Net loss for Q1 2026 was $3.2 million, a 10% improvement compared to the same period last year. The improvement was due to cost optimization measures and increased revenue.
Research and Development Expenses R&D expenses were $1.8 million, up 15% year-over-year. The increase was driven by investments in advancing the clinical pipeline.
General and Administrative Expenses G&A expenses were $1.2 million, a 5% decrease year-over-year, reflecting cost-saving initiatives.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Dual Path Approach: Commercializing proprietary formulations through 503B compounding while pursuing FDA approval, and advancing select solutions as branded consumer health products that do not require a prescription.
Expanded Business Strategy: The company is executing an expanded business strategy focused on a dual path approach to bring innovative women's health solutions to market efficiently and quickly.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Risks: The company's dual path approach involves pursuing FDA approval for proprietary formulations, which carries inherent risks of delays or rejections in the regulatory process.
Market Entry Challenges: Commercializing proprietary formulations through 503B compounding and branded consumer health products may face challenges in market acceptance and competition.
Strategic Execution Risks: The expanded business strategy's success depends on efficient execution, which could be impacted by operational inefficiencies or mismanagement.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Dual Path Approach: Commercializing proprietary formulations through 503B compounding while pursuing FDA approval, and advancing select solutions as branded consumer health products that do not require a prescription.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Bioscience result
Brian Kemp
Brookline Capital
CEO President
Capital Markets
Dare Bioscience
Dare President
Director Brian
Division PM
Dolliver Brookline
EDT Ladies
Financial Officer
Johnson CEO
Kemp Dolliver
King today
LLC Research
Ladies gentleman
Layton statement
Markets LLC
Officer Sabrina
Officer Secretary
PM EDT
President Principal
Principal Financial
Research Division
Sabrina Johnson
conference Dare
gentleman conference
name King
today Dare
DARE Transcript
Daré Bioscience, Inc. (DARE) Q1 2026 Earnings Call Transcript
Unknown5-14
The earnings call indicates a mixed outlook. The 25% revenue growth is positive, but the net loss and increased R&D expenses raise concerns. The dual path strategy offers potential but carries regulatory and execution risks. No new partnerships or changes in guidance were mentioned, and shareholder return plans were not discussed. Without information on market cap, a neutral sentiment is appropriate, reflecting balanced positive and negative factors.
Daré Bioscience, Inc. (DARE) Q4 2025 Earnings Call Transcript
Unknown3-26
The company's reliance on non-dilutive funding and limited working capital pose sustainability concerns. Competitive pressures and strategic execution risks further exacerbate these issues. Despite decreasing expenses, the potential for constrained operational flexibility and unclear management responses in the Q&A section contribute to a negative sentiment. The lack of new partnerships or strong positive catalysts, coupled with competitive pressures in a challenging market, suggests a negative stock price movement in the short term.
Daré Bioscience, Inc. (DARE) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call reveals financial constraints with limited cash reserves and working capital, increased G&A expenses, and decreased R&D spending. While management is optimistic about product launches and partnerships, the market entry challenges, competitive pressures, and supply chain risks pose significant uncertainties. The Q&A section highlights the company's strategic focus but also underscores financial limitations and the need for careful execution. Overall, the negative financial health and strategic risks outweigh positive developments, leading to a negative sentiment rating.
Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript
Unknown8-14
The earnings call presents a mixed outlook. Positive factors include strategic partnerships, grant funding, and a strengthened balance sheet. However, financial constraints, regulatory hurdles, and market competition pose significant risks. The company's dual-path strategy and product pipeline are promising, but uncertainties in execution and economic conditions temper optimism. Overall, the sentiment is neutral, with potential for both positive and negative market reactions.
DARE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
